文献速递青光眼

核苷与核苷酸逆转录酶抑制剂使用与All of Us中原发性开角型青光眼风险的关联

Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us.
PubMed 文献 · Ophthalmology · 2025-06-21

基于美国NIH All of Us数据库中305441名≥40岁且有链接电子健康记录者,采用1:10倾向评分匹配的回顾性队列研究,发现核苷与核苷酸逆转录酶抑制剂(NRTI)使用者原发性开角型青光眼(POAG)风险升高(OR 2.21,95%CI 1.48-3.28,P<0.001),校正残余失衡后仍显著(OR 1.84,95%CI 1.22-2.77,P=0.004)。

要点

  • NRTI使用者POAG发生率为4.32%(31例),匹配对照组为2.00%(144例)。
  • NRTI使用与POAG风险升高相关(OR 2.21,95%CI 1.48-3.28,P<0.001)。
  • 校正家族史、HIV及乙肝诊断残余失衡后关联仍显著(OR 1.84,95%CI 1.22-2.77,P=0.004)。

核心结论

  • 在倾向评分匹配协变量并校正残余失衡后,NRTI使用与更高的POAG风险相关。

研究设计与样本

  • 回顾性队列研究,纳入美国NIH All of Us数据库中≥40岁且有链接电子健康记录者,排除使用NRTI前已诊断POAG者。
  • 采用1:10倾向评分匹配创建NRTI使用者与非使用者队列,匹配因素包括年龄、种族、出生时性别、HIV诊断、乙肝诊断及POAG家族史。
  • 使用多变量逻辑回归校正残余失衡,并针对自我报告的眼科医生就诊进行敏感性分析。

主要发现

  • 在305441名≥40岁且有链接电子健康记录的All of Us参与者中,识别出718名(0.24%)NRTI使用者。
  • NRTI使用者POAG发生率为4.32%(N=31),倾向评分匹配对照组(N=7180)为2.00%(N=144)。
  • NRTI使用与POAG风险升高相关(OR 2.21,95%CI 1.48-3.28,P<0.001)。
  • 校正POAG家族史、HIV诊断及乙肝诊断的残余失衡后,任何NRTI使用仍与POAG风险升高显著相关(OR 1.84,95%CI 1.22-2.77,P=0.004)。
  • 匹配并校正自我报告的眼科医生就诊后,NRTI仍与POAG风险显著相关(OR 2.30,95%CI 1.07-4.96,P=0.033)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the association between the systemic use of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) and primary open-angle glaucoma (POAG). DESIGN: Retrospective cohort study. PARTICIPANTS: Individuals aged ≥40 years with linked electronic health record (EHR) data in the National Institutes of Health (NIH) All of Us dataset. Participants with a diagnosis of POAG before the use of NRTIs were excluded. METHODS: A cohort of 1:10 NRTI users to nonusers was created using a propensity score matching design, considering age, race, sex at birth, human immunodeficiency virus (HIV) diagnosis, hepatitis B diagnosis, and family history of POAG. A multivariable logistic regression model was used to adjust for residual imbalance. Sensitivity analyses were performed for self-reported eye doctor visits. MAIN OUTCOME MEASURE: Diagnosis of POAG. RESULTS: Among the 305 441 All of Us participants aged ≥40 years with a linked EHR, we identified 718 individuals (0.24%) with NRTI use, excluding participants with a diagnosis of POAG before NRTI exposure. The rate of POAG in the NRTI users was 4.32% (N = 31). The rate of POAG in the propensity score-matched control group (N = 7180) was 2.00% (N = 144). Use of NRTI was associated with an increased risk of POAG (odds ratio [OR], 2.21; 95% confidence interval [CI], 1.48-3.28; P < 0.001). When adjusting for residual imbalance of family history of POAG, HIV diagnosis, and hepatitis B diagnosis, use of any NRTIs remained significantly associated with an increased risk of developing POAG (OR, 1.84; 95% CI, 1.22-2.77; P = 0.004). After matching and adjusting for self-reported eye doctor visits, NRTIs remained significantly associated with POAG risk (OR, 2.30; 95% CI, 1.07-4.96; P = 0.033). CONCLUSIONS: Use of NRTIs was associated with a higher risk of POAG with propensity score matching for covariates and adjusting for residual imbalances. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Pham K, Jin F, Lee R, et al. Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us. Ophthalmology. 2025. PMID: 40550363. doi:10.1016/j.ophtha.2025.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。